SAN DIEGO, Feb. 27, 2019 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of patients diagnosed with
cancer, announces that it will collaborate with Providence St.
Joseph Health, Southern
California, and its wholly owned affiliates Providence Saint
John's Health Center and the John Wayne Cancer Institute, to
conduct a study to validate the use of cerebrospinal fluid (CSF) as
a specimen type with Biocept's Target Selector™ liquid biopsy
platform.
In patients diagnosed with certain cancers, leptomeningeal
metastases (LM) can occur when tumor cells gain access to CSF
pathways and regrow in distant sites within the spinal cord and
brain. Biocept's liquid biopsy platform will be used to test
the CSF of patients diagnosed with certain types of cancer, such as
breast, lung and melanoma, as well as other malignancies to
determine if LM has occurred. The results from Biocept's liquid
biopsy testing will be compared to standard methods for confirming
the diagnosis of LM.
"We look forward to using Biocept's Target Selector™ technology
to evaluate oncologic biomarkers in the CSF of patients with
cancer, with the potential to validate a rapid and accurate
solution for confirming LM," stated Santosh
Kesari, MD, PhD, Chairman and Professor, Department of
Translational Neurosciences and Neurotherapeutics, Director of
Neuro-oncology at the Pacific Neuroscience Institute and John Wayne
Cancer Institute. "This study is aimed at addressing a major
need in the treatment of metastatic disease, given the devastating
nature of LM involvement in many cancer types."
"We are very pleased to collaborate with Dr. Kesari and
Providence St. Joseph Health in this study designed to further
validate the clinical utility of our Target Selector™ platform
using the CSF of patients with cancer," said Michael W. Nall, President and CEO of Biocept.
"Among the significant advantages of our liquid biopsy technology
is its versatility, which enables its application in a variety of
clinical situations and for use with multiple types of biofluids.
Results of this study could open new market opportunities for
Biocept."
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
information for treating and monitoring patients diagnosed with
cancer. The Company's patented Target Selector™ liquid biopsy
technology platform captures and analyzes tumor-associated
molecular markers in both circulating tumor cells (CTCs) and in
plasma (ctDNA). With thousands of tests performed, the platform has
demonstrated the ability to identify cancer mutations and
alterations to inform physicians about a patient's disease and
therapeutic options. For additional information, please
visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to our ability to improve the
outcomes of patients diagnosed with cancer, our ability to validate
a rapid and accurate solution for confirming LM, our ability to
validate the clinical utility of our Target Selector™ platform
using the CSF of patients with cancer, and our ability to open
new market opportunities for our proprietary technology platform,
such statements are forward-looking, and are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The reader is cautioned not to put undue reliance on
these forward-looking statements, as these statements are subject
to numerous risk factors as set forth in our Securities and
Exchange Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at https://www.sec.gov.
Contact:
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-and-providence-saint-johns-health-center-collaborate-to-evaluate-cerebrospinal-fluid-for-use-with-liquid-biopsy-testing-in-metastatic-cancer-300802899.html
SOURCE Biocept, Inc.